A Leader in the Discovery and Development of First- and Best-in-class Small Molecule Cancer Therapies

Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs. For more than two decades, our founders and team have leveraged their deep expertise to develop our proprietary drug discovery platform to pursue particularly challenging targets. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators that restore programmed cell death. Our clinical candidates include novel Bcl-2 and Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). We have eleven completed or ongoing international registrational trials, including two that are FDA-regulated.